Every Day Matters
Janux Therapeutics (januxrx.com) scores 70 out of 100 on Brand Analyzer, placing it in the Developing tier among Healthcare brands, in the 22nd percentile of 14679 Healthcare brands.
Janux Therapeutics is a biopharmaceutical company developing novel immunotherapies that selectively modulate T cells to treat cancer and autoimmune diseases. Its approach aims to achieve targeted efficacy while avoiding the systemic toxicity often associated with other immune-modulating treatments. The company engineers precision T cell therapies intended to improve patient outcomes, positioning itself as an innovator in the T cell immunotherapy space for both oncology and autoimmune indications.
| Brand Name | Janux Therapeutics |
|---|---|
| Domain | januxrx.com |
| Industry | Healthcare |
| Main Competitors | Amgen (90/100), Regeneron Pharmaceuticals (92/100), Xencor (75/100), Harpoon Therapeutics, Genentech (Roche) (84/100), Compugen (85/100), Sonoma Biotherapeutics |
Moz Domain Authority 36/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #3,617,710 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Janux is developing novel immunotherapies that selectively modulate T cells to fight cancer and autoimmune diseases without causing systemic safety issues." (Meta description: 21 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, Instagram; no detected presence on X (Twitter), Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Janux Therapeutics?", Claude could identify the brand as of October 2026. Janux Therapeutics is a clinical-stage biopharmaceutical company developing novel T cell engager therapies for cancer using its proprietary Tumor Activated T Cell Engager (TRACTr) platform, designed to improve the safety and efficacy of these treatments. Its lead programs include Best known for Its TRACTr platform technology for developing safer T cell engager immunotherapies for cancer.
When asked "Best brands similar to Janux Therapeutics?", Claude would recommend Janux Therapeutics as of October 2026. It's a notable name in the T cell engager and oncology biotech space, so it would come up when discussing innovative cancer immunotherapy companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Janux Therapeutics's main competitors in Healthcare: Amgen (90/100), Regeneron Pharmaceuticals (92/100), Xencor (75/100), Genentech (Roche) (84/100), Compugen (85/100).
Sources: Brand Analyzer scan
Janux Therapeutics is a biopharmaceutical company focused on developing novel immunotherapies that selectively modulate T cells to treat cancer and autoimmune diseases.
Sources: Janux Therapeutics official site
Janux Therapeutics has low AI-search visibility, scoring 18/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 23, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Janux Therapeutics official site
Janux Therapeutics develops precision-engineered T cell immunotherapies designed to selectively target disease-such as cancer and autoimmune conditions-while minimizing the systemic toxicity common to other immune-modulating treatments.
Sources: Janux Therapeutics official site
Janux Therapeutics offers novel T cell immunotherapies designed to treat cancer and autoimmune diseases by selectively modulating T cell activity while avoiding systemic toxicity.
Sources: Janux Therapeutics official site
Janux Therapeutics scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Janux Therapeutics official site
Janux Therapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Janux Therapeutics official site
Janux Therapeutics is known for its approach to engineering T cell immunotherapies that aim to selectively target diseased cells or tissues, reducing the systemic safety issues often seen with other immune-modulating therapies.
Sources: Janux Therapeutics official site
Janux Therapeutics' work is intended for patients with cancer and autoimmune diseases, and its research and development activities engage healthcare providers, clinical researchers, and biopharmaceutical industry partners seeking advanced immunotherapy solutions.
Sources: Janux Therapeutics official site
Janux Therapeutics scores 18/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Janux Therapeutics has a weak AI-visibility profile at 18/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (0/100). It benefits from a global traffic rank of #3,617,710 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 36/100. In a live check, Claude could already identify Janux Therapeutics from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Janux Therapeutics: Janelia Research Campus (70/100), IVIRMA Global (70/100), Journal of Lipid Research (70/100), JRS (70/100).
A step up - brands to learn from: ZT Corporate (71/100), Zorgnet-Icuro (71/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.